Bavarian Nordic options Prostvac to BMS; option exercise unlikely
Bristol-Myers Squibb Co. received an option to exclusively license Bavarian Nordic AS's Phase III Prostvac (rilimogene galvacirepvec), a vaccine for asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC).
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.